Başkent Üniversitesi Makaleler

Permanent URI for this collectionhttps://hdl.handle.net/11727/13096

Browse

Filters

2012 - 20132

Settings

search.filters.applied.f.language: search.filters.language.enSubject: search.filters.subject.Outcome

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Long-Term Outcome of Reusing a Kidney Allograft Retrieved From a Living Recipient and Retransplanted Into a Second Recipient
    (Başkent Üniversitesi, 2013-04) Bellière, Julie; Rostaing, Lionel; Kamar, Nassim; Guilbeau-Frugier, Céline; Sallusto, Federico
    This case report shows that the 5-year outcome of a reused kidney from live-kidney allograft recipients because of intractable recurrence of thrombotic microangiopathy was excellent.
  • No Thumbnail Available
    Item
    HLA Tissue Typing Has No Effect on the Outcome of Patients Undergoing a Living-donor Liver Transplant: A Single-center Experience in Egypt
    (Başkent Üniversitesi, 2012-04) Ayman Yosry,; Abdel-Bary, Akram; Hosny, Yaser Hatata Adel; Doss, Wahid; Kamel, Sanna; Saad, Yasmin; Omran, Dalia; Omar, Ashraf; Al-Serafy, Magdy; Esmat, Gamal; Said, Mohamed
    Objectives: To analyze the effect of human leukocyte antigen tissue typing on outcome of live-donor liver transplant. Materials and Methods: Fifty recipients underwent live-donor liver transplant in the Dar Al-Fouad Hospital in Egypt and were retrospectively evaluated. Patients were classified into 2 groups: those with human leukocyte antigen +ve, and those with human leukocyte antigen -ve and donors. Hepatitis C virus-related end-stage liver disease was the main indication for transplant. Demographic data, preoperative laboratory data, results of human leukocyte antigen tissue typing, Child score, model for end-stage liver disease score, graft/recipient weight-ratio, ischemia times, surgical complications, postoperative laboratory data, liver biopsy, immunosuppression, and pulse steroids were collected. Graft and patient survivals were studied using Kaplan-Meier curves. Results: The mean model end-stage liver disease score was 18 ± 3.61 in group 1 and 17.73 ± 3.72 in group 2, with no significant difference. Graft/recipient weight ratio, ischemia times, and postoperative complications showed P = NS. Cyclosporine and tacrolimus were used in 5/9, 8/41, and 4/9 in group 1, and 32/41 in group 2 (P = NS). Rejection and pulse steroids were reported in 3/9 and 12/41 of group 1, and 3/12 and 11/41 of group 2 (P = NS). Hepatitis C virus-recurrence was diagnosed in 5/9 of patients (55%) and 8/41 of patients (29.5%) in groups 1 and 2 (P < .05). No statistical difference was found regarding mortality; 5-year patient and graft survival was 35/50 (70% in group 1 [human leukocyte antigen +ve]), 7/9 (77.8%), and 28/41 in group 2 (68.3%) (human leukocyte antigen -ve). Conclusions: Positive human leukocyte antigen typing before live-donor liver transplant has no effect on the incidence of postoperative complications, rejection episodes, and patient or graft survival. Recipients with positive human leukocyte antigen typing may have increased risk of hepatitis C virus-recurrence after live-donor liver transplant.